Reasons why cabergoline is not marketed in China

Cabergoline, a long-acting dopamine receptor agonist and prolactin inhibitor, has been widely used around the world to treat hyperprolactinemia, Parkinson's disease and other diseases. However, what is puzzling is that despite its remarkable efficacy, it is difficult to find it in the Chinese market. What is the reason behind this?

The primary reason is that China’s approval standards and procedures for new drugs are quite strict. Any new drug that wants to be launched in China must go through a series of rigorous clinical trials, detailed registration applications, and layers of administrative approvals. The establishment of this system aims to ensure the safety and therapeutic effect of drugs to the public to the greatest extent. Unfortunately, cabergoline has not yet been approved for clinical trials in China, so it cannot cross this critical approval stage and cannot be legally sold and used in the country.

In addition, the Chinese market already has a variety of options for drugs to treat Parkinson's disease, hyperprolactinemia and other diseases. These marketed drugs have excellent clinical performance, so the market does not show strong expectations for the new drug cabergoline. When there are already many effective therapeutic drugs, the introduction of new drugs often requires more capital investment and marketing, which undoubtedly increases the difficulty for cabergoline to enter the Chinese market.

For those patients who do need cabergoline treatment, they may be able to obtain the drug through formal overseas channels. Currently, there are both original drugs and Indian versions of generic drugs available on the market, and the prices of these drugs vary. However, no matter which medicine is chosen, it must be used under the guidance of a professional doctor to ensure that it is suitable for the patient's specific condition.

In short, the reasons why cabergoline failed to be launched in China mainly include the strict process of new drug approval, market competition of existing therapeutic drugs, and market demand. Although patients may obtain the drug through overseas channels, they still need to consult a professional doctor to ensure its safety and suitability before use.